506 related articles for article (PubMed ID: 29157685)
61. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
62. Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
Milkiewicz KL; Aimone LD; Albom MS; Angeles TS; Chang H; Grobelny JV; Husten J; Losardo C; Miknyoczki S; Murthy S; Rolon-Steele D; Underiner TL; Weinberg LR; Worrell CS; Zeigler KS; Dorsey BD
Bioorg Med Chem; 2011 Nov; 19(21):6274-84. PubMed ID: 21967808
[TBL] [Abstract][Full Text] [Related]
63. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
64. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
65. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
66. Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Yang X; Fan D; Troha AH; Ahn HM; Qian K; Liang B; Du Y; Fu H; Ivanov AA
Bioorg Med Chem; 2021 Sep; 45():116324. PubMed ID: 34333394
[TBL] [Abstract][Full Text] [Related]
67. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
Fang JD; Lee SL
Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
[TBL] [Abstract][Full Text] [Related]
68. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
69. Recent advances in c-Met-based dual inhibitors in the treatment of cancers.
Jin F; Lin Y; Yuan W; Wu S; Yang M; Ding S; Liu J; Chen Y
Eur J Med Chem; 2024 Jun; 272():116477. PubMed ID: 38733884
[TBL] [Abstract][Full Text] [Related]
70. Advancing the kinase field: new targets and second generation inhibitors.
Laufer S; Bajorath J
J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
[No Abstract] [Full Text] [Related]
71. MET receptor in oncology: From biomarker to therapeutic target.
Malik R; Mambetsariev I; Fricke J; Chawla N; Nam A; Pharaon R; Salgia R
Adv Cancer Res; 2020; 147():259-301. PubMed ID: 32593403
[TBL] [Abstract][Full Text] [Related]
72. Gene of the month: MET.
Skead G; Govender D
J Clin Pathol; 2015 Jun; 68(6):405-9. PubMed ID: 25987653
[TBL] [Abstract][Full Text] [Related]
73. The multiple paths towards MET receptor addiction in cancer.
Duplaquet L; Kherrouche Z; Baldacci S; Jamme P; Cortot AB; Copin MC; Tulasne D
Oncogene; 2018 Jun; 37(24):3200-3215. PubMed ID: 29551767
[TBL] [Abstract][Full Text] [Related]
74. An updated patent review of small-molecule c-Met kinase inhibitors (2018-present).
Chu C; Rao Z; Pan Q; Zhu W
Expert Opin Ther Pat; 2022 Mar; 32(3):279-298. PubMed ID: 34791961
[TBL] [Abstract][Full Text] [Related]
75. Aberrant
Al-Ghabkari A; Huang B; Park M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
[TBL] [Abstract][Full Text] [Related]
76. C-MET inhibitors in the treatment of lung cancer.
Goździk-Spychalska J; Szyszka-Barth K; Spychalski L; Ramlau K; Wójtowicz J; Batura-Gabryel H; Ramlau R
Curr Treat Options Oncol; 2014 Dec; 15(4):670-82. PubMed ID: 25266653
[TBL] [Abstract][Full Text] [Related]
77. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
Sattler M; Salgia R
Curr Oncol Rep; 2007 Mar; 9(2):102-8. PubMed ID: 17288874
[TBL] [Abstract][Full Text] [Related]
78. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
Kim KH; Kim H
Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
[TBL] [Abstract][Full Text] [Related]
79. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
[TBL] [Abstract][Full Text] [Related]
80. Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions.
Cerchia C; Lavecchia A
Curr Med Chem; 2017; 24(21):2312-2344. PubMed ID: 28413965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
